20 articles
Breakthrough review reveals how modern diabetes treatments protect multiple organs and may extend healthy lifespan through novel mechanisms.
Amgen expands late-stage testing of its long-acting obesity drug MariTide, including a trial for patients switching from rival GLP-1 medications.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
Scientists discover how tumors use glucose to survive lysosome-blocking drugs, revealing promising combination therapies.
New study suggests Lilly's tirzepatide leads to more lean muscle loss compared to Novo's semaglutide, despite superior weight loss results.
Blocking zinc transport in stem cell-derived pancreatic islets improves their survival and function after transplantation for diabetes treatment.
Breakthrough crystal technology enables transplanted insulin-producing cells to survive and function for a full year without traditional immunosuppression.
Adding a vascular network to stem cell-derived islet organoids dramatically improves beta-cell calcium signaling, insulin secretion, and diabetes reversal in mice.
Pharmaceutical giants clash over obesity drug superiority claims as Lilly's new pill gets FDA approval and Novo fights back with competing data.
New research reveals how high blood sugar directly impairs muscle stem cells, leading to weaker muscles and poor injury recovery.
Study shows intensive glucose management increases cardiac stem cells in heart attack patients, potentially improving recovery.
Scientists discover NKX6.1 gene expression can predict which pancreatic islet transplants will succeed in treating type 1 diabetes.
Dasatinib + quercetin clears senescent kidney cells, restores anti-aging protein Klotho, and reverses transcriptional aging across multiple renal cell types.
New wearable and non-invasive glucose monitors are transforming diabetes care — here's what's available and how they work.
A second wave of RAS-targeting therapies is reshaping cancer treatment, with implications for longevity through better tumor control.
Eli Lilly suggests lower doses of tirzepatide may safely sustain weight loss at potentially lower cost, opening new options for long-term obesity management.
ProcyanidinC1, a natural senolytic, selectively eliminates senescent cells in diabetic skin, dramatically improving wound healing in mouse models.
Three days of GDF11 infusion post-injury preserved pericytes, protected the blood-spinal cord barrier, and improved functional recovery in mice.
With brensocatib now approved, researchers are mapping the next wave of therapies for this chronic, underserved lung disease.
Novel nanogel therapy targets mitochondrial ROS to break the inflammation-hypoxia cycle in periodontitis, showing strong preclinical results.
